La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Argenica Therapeutics Dividende

Dividende contrôle des critères 0/6

Argenica Therapeutics n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	2.1%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-AU$0.043
Prévision de rendement du dividende	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de AGN ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de AGN ont augmenté.

Rendement des dividendes par rapport au marché

Argenica Therapeutics Rendement des dividendes par rapport au marché

Comment le rendement du dividende de AGN se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (AGN)	n/a
25% du marché (AU)	2.6%
25% du marché (AU)	6.0%
Moyenne du secteur (Pharmaceuticals)	2.1%
Analyste prévisionnel (AGN) (jusqu'à 3 ans)	n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de AGN par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de AGN par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de AGN afin de déterminer si ses paiements de dividendes sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car AGN n'a signalé aucun versement.

Argenica Therapeutics Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Argenica Therapeutics Limited has completed an IPO in the amount of AUD 7 million.

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés